Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EYES Second Sight Medical Products (EYES) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Second Sight Medical Products Stock (NASDAQ:EYES) 30 days 90 days 365 days Advanced Chart Get EYES alerts:Sign Up Key Stats Today's Range N/A50-Day Range$4.11▼$13.0552-Week Range N/AVolume36,800 shsAverage Volume132,982 shsMarket Capitalization$54.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSecond Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.Read More… Receive EYES Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter. Email Address EYES Stock News HeadlinesStartups Like Science and Musk's Neuralink Aim to Help Blind People SeeNovember 13, 2024 | msn.comEye drops claiming to change eye color raise alarm among eye specialists on TikTokNovember 12, 2024 | msn.comBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin Skimming allows you to “skim” cash into your account thanks to 2025’s surging Bitcoin market.February 18, 2025 | Brownstone Research (Ad)I Tried PRFM Injections, the Ultimate Undereye Filler AlternativeNovember 9, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Vivani Medical (VANI) with Buy RecommendationNovember 7, 2024 | msn.comDoes Guy Win The Golden Bachelorette? Joan Hinted at Where They Stand NowNovember 6, 2024 | msn.comOprah Winfrey Issues Stark Warning to Those Planning Not to VoteNovember 5, 2024 | msn.comQ3 2024 GeneDx Holdings Corp Earnings CallOctober 31, 2024 | finance.yahoo.comSee More Headlines EYES Stock Analysis - Frequently Asked Questions How were Second Sight Medical Products' earnings last quarter? Second Sight Medical Products, Inc. (NASDAQ:EYES) released its quarterly earnings results on Monday, June, 29th. The medical device company reported ($1.71) EPS for the quarter, missing analysts' consensus estimates of ($1.23) by $0.48. When did Second Sight Medical Products' stock split? Shares of Second Sight Medical Products reverse split on Friday, August 19th 2022. The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Second Sight Medical Products IPO? Second Sight Medical Products (EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO. What other stocks do shareholders of Second Sight Medical Products own? Based on aggregate information from My MarketBeat watchlists, some other companies that Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Shopify (SHOP). Company Calendar Last Earnings6/29/2020Today2/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:EYES CUSIPN/A CIK1266806 Webwww.secondsight.com Phone(818) 833-5000Fax818-833-5067Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.58% Return on Assets-13.02% Debt Debt-to-Equity RatioN/A Current Ratio22.15 Quick Ratio22.15 Sales & Book Value Annual Sales$3.38 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / BookN/AMiscellaneous Outstanding Shares13,135,000Free Float6,935,000Market Cap$54.38 million OptionableOptionable Beta2.55 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:EYES) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored(1) Elon Musk’s Final Project REVEALEDThe world’s richest man has an ace up his sleeve. You see, while everyone is talking about Elon Musk’s plan...Paradigm Press | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Second Sight Medical Products, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Second Sight Medical Products With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.